MRNA’s Nasdaq-100 Inclusion Draws Retail Attention to SLS and IBRX
Moderna’s Nasdaq-100 inclusion may increase index-related attention, while retail traders compare smaller biotech names SLS and IBRX.
AbbVie Wins FDA Approval for JUVMO Parkinson’s Therapy: What ABBV Investors Should Watch
AbbVie’s FDA approval of JUVMO adds a Parkinson’s therapy to its neuroscience portfolio, but commercial execution remains the next test.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Needham’s Buy Rating Puts LB Pharmaceuticals’ 2027 Trial Catalyst in the Spotlight
Needham’s Buy initiation highlights LB Pharmaceuticals ahead of the pivotal NOVA-2 schizophrenia readout expected in the…
Pfizer’s Tilrekimig Advances to Phase 3 as Investors Seek New Growth Drivers
Pfizer’s tilrekimig met its Phase 2 goal and is advancing to Phase 3, but the program remains an opportunity—not proof o…
AbbVie’s JUVMO Approval Puts 41% Undervaluation Thesis in Focus
AbbVie’s JUVMO approval strengthens its pipeline narrative, while Simply Wall St’s 41% undervaluation estimate remains a…
September Payrolls Miss by 61,000 as Treasury Traders Reassess Fed Rate-Cut Bets
A weak September jobs report and $60,000 two-month downward revision put Fed rate-cut expectations, Treasury yields and …
United Therapeutics Jumps 13.2% After FDA Accepts Supplemental Tyvaso Application
United Therapeutics shares traded up 13.2% after FDA acceptance of a supplemental Tyvaso application and an announced bu…
onsemi Raises Synaptics Offer to $123 a Share as Semiconductor M&A Accelerates
onsemi’s revised $123-per-share cash offer for Synaptics highlights semiconductor valuation debates and possible M&A ben…
Q32 Bio Slides 13.2% as Oppenheimer Defends Rating Despite Bempikibart Data Concerns
Q32 Bio fell 13.2% as investors questioned bempikibart’s efficacy, while Oppenheimer maintained its rating and highlight…
AbbVie’s Rinvoq Vitiligo Data Set Up Q4 FDA Catalyst for ABBV Investors
Rinvoq’s promising vitiligo results and expected Q4 2026 FDA decision add a potential growth catalyst, though dividend c…
Wave Life Sciences Shares Rise as FDA Confirms Registrational Pathway for WVE-006
FDA alignment on WVE-006 trial design gives Wave Life Sciences a clearer regulatory path, but execution and clinical val…